Results from trials of two potential COVID-19 vaccines yielded initial signs of efficacy with no serious adverse side effects, according to early data released on Monday. One was a UK study of the candidate being developed by Oxford University and British drugmaker AstraZeneca. Both vaccines use a modified, harmless common cold virus known as an adenovirus to deliver genetic instructions to cells for inducing an immune response against the novel coronavirus.
Source:: Yahoo News